Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients

References

• Shanbhogue W, Mitchell DM, Rosen CJ, et al. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4(2):159–173.
   PubMed Web of Science ®Google Scholar
• Jouanny P, Guillemin F, Kuntz C, et al. Environmental and genetic factors affecting bone mass, Similarity of bone density among members of healthy families. Arthritis Rheum. 1995;38(1):61–67.
   PubMedGoogle Scholar
• Pan H, Wu N, Yang T, et al. Association between bone mineral density and type 1 diabetes mellitus: a meta-analysis of cross-sectional studies. Diabetes Metab Res Rev. 2014;30(7):531–542.
   PubMed Web of Science ®Google Scholar
• Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(10):3744–3750.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. Jama. 2011;305(21):2184–2192.
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643.
   PubMed Web of Science ®Google Scholar
• Burgers TA, Williams BO. Regulation of Wnt/β-catenin signaling within and from osteocytes. Bone. 2013;54(2):244–249.
   PubMed Web of Science ®Google Scholar
• Honasoge M, Rao AD, Rao SD. Sclerostin: recent advances and clinical implications. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):437–446.
   PubMed Web of Science ®Google Scholar
• Voorzanger-Rousselot N, Goehrig D, Facon T, et al. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol. 2009;145(2):264–266.
   PubMed Web of Science ®Google Scholar
• Drake MT, Srinivasan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95(11):5056–5062.
   PubMed Web of Science ®Google Scholar
• Starup-Linde J, Lykkeboe S, Gregersen S, et al. Bone structure and predictors of fracture in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2016;101(3):928–936.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(10):4030–4037.
   PubMed Web of Science ®Google Scholar
• Ardawi MSM, Akhbar DH, AlShaikh A, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56(2):355–362.
   PubMed Web of Science ®Google Scholar
• Garcia-Martín A, Reyes-Garcia R, García-Fontana B, et al. Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus. PLoS One. 2014;9(11):e111703.
   PubMed Web of Science ®Google Scholar
• Morvan F, Boulukos K, Clément-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934–945.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther. 2013;13(2):183–196.
   PubMed Web of Science ®Google Scholar
• Jin H, Wang B, Li J, et al. Anti-DKK1 antibody promotes bone fracture healing through activation of β-catenin signaling. Bone. 2015;71:63–75.
   PubMed Web of Science ®Google Scholar
• Feng D, Liu T, Wang H, et al. Mediation role of C-reactive protein on the association between smoking quantity and type 2 diabetes in current Chinese smokers. J Diabetes Res. 2014;2014:171538.
   PubMed Web of Science ®Google Scholar
• Devesa García C, Matoses Chirivella C, Peral Ballester L, et al. Pharmaceutical care in renal insufficiency inpatients. Farm Hosp. 2012;36(6):483–491.
   PubMedGoogle Scholar
• Dimai HP. Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases. Bone. 2016;104:39–43.
   PubMed Web of Science ®Google Scholar
• Zhang W, Drake MT. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr Osteoporos Rep. 2012;10(1):93–100.
   PubMed Web of Science ®Google Scholar
• Antonopoulou M, Bahtiyar G, Banerji MA, et al. Diabetes and bone health. Maturitas. 2013;76 (3):253–259.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32–38.
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–163.
   PubMed Web of Science ®Google Scholar
• Hamann C, Rauner M, Höhna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013;28(3):627–638.
   PubMed Web of Science ®Google Scholar
• Dovjak P, Dorfer S, Föger-Samwald U, et al. Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014;60(6):493–501.
   PubMed Web of Science ®Google Scholar
• Kirmani S, Amin S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int. 2012;23(3):1123–1130.
   PubMed Web of Science ®Google Scholar
• Piec I, Washbourne C, Tang J, et al. How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif Tissue Int. 2016;98(6):546–555.
   PubMed Web of Science ®Google Scholar
• Eslaminejad MB, Mirzadeh H, Nickmahzar A, et al. Type I collagen gel in seeding medium improves murine mesencymal stem cell loading onto the scaffold, increases their subsequent proliferation, and enhances culture mineralization. J Biomed Mater Res B Appl Biomater. 2009;90(2):659–667.
   PubMedGoogle Scholar
• Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012;23(2):635–641.
   PubMed Web of Science ®Google Scholar
• Cavalier E, Lukas P, Carlisi A, et al. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease. Clin Chim Acta. 2013;425:117–118.
   PubMed Web of Science ®Google Scholar
• Van Bezooijen RL, Ten Dijke P, Papapoulos SE, et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16(3):319–327.
   PubMed Web of Science ®Google Scholar
• Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM dependent mechanism. J Bone Miner Res. 2011;26(7):1425–1436.
   PubMed Web of Science ®Google Scholar
• Ryan ZC, Ketha H, McNulty MS, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA. 2013;110(15):6199–6204.
   PubMed Web of Science ®Google Scholar
• Pye SR, Ward KA, Cook MJ, et al. Bone turnover predicts change in volumetric bone density and bone geometry at the radius in men. Osteoporos Int. 2017;28(3):935–944.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Li A, Song YL, et al. Role of sclerostin in the bone loss of postmenopausal Chinese women with type 2 diabetes. Chin Med Sci J. 2012;28(3):135–139.
   Google Scholar
• Spencer GJ, Utting JC, Etheridge SL, et al. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006;119(Pt 7):1283–1296.
   PubMed Web of Science ®Google Scholar
• Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751–764.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hu CH, Zhou CH, et al. DKK1 rescues osteogenic differentiation of mesenchymal stem cells isolated from periodontal ligaments of patients with diabetes mellitus induced periodontitis. Sci Rep. 2015;5:13142.
   PubMed Web of Science ®Google Scholar
• Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996;97(1):14–21.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yoon SY, Lim SK, et al. The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes. Int J Endocrinol. 2014;2014:715908.
   PubMed Web of Science ®Google Scholar
• Jou YC, Tsai YS, Hsieh HY, et al. Age-dependent association between Dickkopf-1 and calcium-containing urolithiasis. Urology. 2014;83(5):1006–1010.
   PubMed Web of Science ®Google Scholar
• Lin CL, Wang JY, Ko JY, et al. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol. 2010;21(1):124–135.
   PubMed Web of Science ®Google Scholar
• González-Molero I, Rojo-Martínez G, Morcillo S, et al. Hypovitaminosis D and incidence of obesity: a prospective study. Eur J Clin Nutr. 2013;67(6):680–682.
   PubMed Web of Science ®Google Scholar
• Viapiana O, Fracassi E, Troplini S, et al. Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int. 2013;92(4):324–329.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Laughlin GA, Li H, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2012;27(11):2306–2313.
   PubMed Web of Science ®Google Scholar
• Mercer KE, Wynne RA, Lazarenko OP, et al. Vitamin D supplementation protects against bone loss associated with chronic alcohol administration in female mice. J Pharmacol Exp Ther. 2012;343(2):401–412.
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Longterm use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Cmaj. 2009;180(1):32–39.
   PubMed Web of Science ®Google Scholar